BR0307411A - Ligantes alfa2delta para tratar zumbidos - Google Patents

Ligantes alfa2delta para tratar zumbidos

Info

Publication number
BR0307411A
BR0307411A BR0307411-0A BR0307411A BR0307411A BR 0307411 A BR0307411 A BR 0307411A BR 0307411 A BR0307411 A BR 0307411A BR 0307411 A BR0307411 A BR 0307411A
Authority
BR
Brazil
Prior art keywords
ligands
treat tinnitus
treat
tinnitus
tumps
Prior art date
Application number
BR0307411-0A
Other languages
English (en)
Portuguese (pt)
Inventor
David James Dooley
David Juergen Wustrow
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27663234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0307411(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0307411A publication Critical patent/BR0307411A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/131Amines acyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR0307411-0A 2002-01-31 2003-01-20 Ligantes alfa2delta para tratar zumbidos BR0307411A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35363202P 2002-01-31 2002-01-31
PCT/IB2003/000232 WO2003063845A1 (en) 2002-01-31 2003-01-20 Alpha 2 delta ligands to treat tinnitus

Publications (1)

Publication Number Publication Date
BR0307411A true BR0307411A (pt) 2004-12-07

Family

ID=27663234

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307411-0A BR0307411A (pt) 2002-01-31 2003-01-20 Ligantes alfa2delta para tratar zumbidos

Country Status (16)

Country Link
US (2) US7026505B2 (enExample)
EP (1) EP1469841A1 (enExample)
JP (1) JP2005521664A (enExample)
KR (1) KR20040081478A (enExample)
CN (1) CN1625393A (enExample)
AU (1) AU2003201716B2 (enExample)
BR (1) BR0307411A (enExample)
CA (1) CA2474000A1 (enExample)
CL (1) CL2008000613A1 (enExample)
IL (1) IL162028A0 (enExample)
MX (1) MXPA04004105A (enExample)
NZ (1) NZ532624A (enExample)
PL (1) PL371944A1 (enExample)
TW (1) TW200306177A (enExample)
WO (1) WO2003063845A1 (enExample)
ZA (1) ZA200403069B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2004078734A1 (en) 2003-03-07 2004-09-16 Warner-Lambert Company Llc TETRAZOLE AND OXADIAZOLONE SUBSTITUTED β-AMINO ACID DERIVATIVES
PL1622569T3 (pl) 2003-04-24 2016-06-30 Incyte Holdings Corp Pochodne aza spiro alkanów jako inhibitory metaloproteaz
WO2005013888A2 (en) * 2003-05-14 2005-02-17 Cytokinetics, Inc. Compounds, compositions and methods
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
CN101506140B (zh) * 2006-08-24 2014-06-18 百时美施贵宝公司 环状11β-羟类固醇脱氢酶Ⅰ型抑制剂
MX2009005114A (es) * 2006-11-14 2009-07-16 Xenoport Inc Uso de los profarmacos gabapentina y pregabalina para tratar el tinnitus.
EA200970487A1 (ru) * 2006-12-08 2009-12-30 Ксенопорт, Инк. Применение пролекарств аналогов гамк для лечения заболеваний
ITMI20071492A1 (it) 2007-07-24 2009-01-25 S I I T Srl Servizio Internazi "composizioni per il trattamento e la prevenzione di condizioni di vertigine e acufeni comprendenti citicolina, estratto di ginkgo biloba e flavoni dimerici di ginkgo biloba"
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
CN101260063B (zh) * 2008-03-21 2013-06-19 北京润德康医药技术有限公司 γ-氨基丁酸衍生物及其制备方法
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
CN111718379A (zh) * 2019-03-19 2020-09-29 海南长安国际制药有限公司 具有l1和l2结构的铂类物质及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
AU733896B2 (en) * 1996-10-23 2001-05-31 Warner-Lambert Company Substituted gamma aminobutyric acids as pharmaceutical agents
EP1475371A1 (en) * 1997-12-16 2004-11-10 Warner-Lambert Company LLC 1-substituted-1-aminomethyl-cycloalkane derivatives (= gabapentin analogues), their preparation and their use in the treatment of neurological disorders
CA2304967C (en) * 1997-12-16 2005-06-14 Warner-Lambert Company 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
EP1400526A3 (en) * 1997-12-16 2004-03-31 Warner-Lambert Company LLC ((cyclo)alkyl substituted)- gamma -aminobutyric acid derivatives (=Gaba analogues), their preparation and their use in the treatment of neurological disorders
KR20010043831A (ko) 1998-05-26 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 칼슘 채널의 알파2델타 서브유닛에 대한 친화력이 있는구조적으로 한정된 아미노산 화합물
GB9821179D0 (en) * 1998-09-30 1998-11-25 Merck Sharp & Dohme Therapeutic use
HRP20020025A2 (en) * 1999-06-10 2003-12-31 Warner Lambert Co Mono- and disubstituted 3-propyl gamma-aminobutyric acids
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
US6620829B2 (en) * 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage

Also Published As

Publication number Publication date
MXPA04004105A (es) 2004-11-29
EP1469841A1 (en) 2004-10-27
PL371944A1 (en) 2005-07-11
CN1625393A (zh) 2005-06-08
KR20040081478A (ko) 2004-09-21
US20060100281A1 (en) 2006-05-11
CL2008000613A1 (es) 2008-11-07
NZ532624A (en) 2007-05-31
US20030176504A1 (en) 2003-09-18
IL162028A0 (en) 2005-11-20
WO2003063845A1 (en) 2003-08-07
JP2005521664A (ja) 2005-07-21
AU2003201716B2 (en) 2008-04-17
TW200306177A (en) 2003-11-16
ZA200403069B (en) 2005-04-22
US7138542B2 (en) 2006-11-21
CA2474000A1 (en) 2003-08-07
US7026505B2 (en) 2006-04-11

Similar Documents

Publication Publication Date Title
BR0317273A (pt) Utilizações farmacêuticas para ligandos alfa2delta
BR0307411A (pt) Ligantes alfa2delta para tratar zumbidos
BR0312729A (pt) Novos derivados de indol-3-enxofre
CY1109242T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου
BR0313942A (pt) Derivados de benzimidazol úteis como agentes antiproliferativos
GT199900139A (es) Derivados de quinolin-2-ona ùtiles como agentes contra el càncer.
BR0312999A (pt) Compostos, composições farmacêticas, método para aumentar a cognição, de tratamento, de inibição da atividade de enzima pde4 em um paciente
BR0210504A (pt) Derivados de naftil-indol substituidos, atuantes como inibidores do inibidor tipo 1 (pai-1) do ativador de plasminogênio
BR0109165A (pt) Método de tratamento de pólipos colÈnicos
CY1111951T1 (el) Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου
PH12023550160A1 (en) Combinations for the Treatment of Cancer
CY1109245T1 (el) Ενωσεις χρησιμες στην θεραπεια ανθρακα και στην αναστολη θανατηφορου παραγοντα
BRPI0415179A (pt) derivados de amida como ligandos de canal de ìon e composições farmacêuticas e métodos de empregar as mesmas
DK0694545T3 (da) Substituerede dibenzoxazepinforbindelser, farmaceutiske sammensætninger og anvendelsesmetoder
BRPI0409230A (pt) formas de dosagem compreendendo ag013736
BRPI0411723A (pt) agente redutor de colesterol no soro ou agente preventivo ou terapêutico para aterosclerose, e, método de dosagem de um agente redutor de colesterol no soro ou agente preventivo ou terapêutico para aterosclerose
BR0308162A (pt) Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso
BR9908125A (pt) Composto, composto dimérico, composição farmacêutica, uso do composto, processo compreendendo inibir células de câncer, e, processo terapêutico
BR0312798A (pt) Derivados de isotiazol úteis como agentes anticancerìgenos
MY145041A (en) Pyrazolopyrimidine derivatives
BR0317263A (pt) Ligantes alfa2delta para o tratamento de fibromialgia e outras perturbações
EP1451182A4 (en) DIMERE COMPOUNDS AND THEIR USE AS ANTIVIRAL AGENTS
AP2001002150A0 (en) Organophosphorous compounds and the use thereof.
BR0303571A (pt) Agente para prevenir ou tratar doenças causadas pela expressão de enos
BR9908452A (pt) Composição fungicida que compreende uma benzoilfeniluréia

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011.